Breaking barriers in Alzheimer’s research with SPEAR UltraDetect pTau 217

Phosphorylated tau at threonine 217 (pTau 217) has emerged as a critical biomarker, distinguishing Alzheimer’s disease (AD) from control with a high degree of specificity. Spear Bio has developed the ultra-sensitive immunoassay SPEAR UltraDetect™ pTau 217, which demonstrates excellent accuracy and specificity distinguishing AD from control via detection of pTau 217. Discover how this technology holds the promise to accelerate the pace of discovery, improve patient outcomes, and bring us closer to conquering AD.